Abstract
Angiotensin converting enzyme (ACE) DD genotype, and plasminogen activator inhibitor (PAI-1) 4G/4G genotype have been reported to affect PAI-1 activity in control subjects and atherosclerotic patients, but no data are available on the influence of angiotensin II type 1 receptor (AT1R) A1166C polymorphism on the inhibitor levels. The degree of fibrinolytic activation after percutaneous transluminal coronary angioplasty (PTCA) has been found to affect the risk of restenosis. The aim of this study was to investigate the possible influence of ACE I/D, AT1R A1166C, and PAI-1 4G/5G polymorphisms on the changes of PAI-1 activity after primary successful percutaneous transluminal angioplasty. In 29 consecutive acute myocardial infarction patients, undergoing primary successful angioplasty, genotyping of ACE I/D, AT1R A1166C, and PAI-1 4G/5G polymorphisms was performed by polymerase chain reaction and restriction fragment length polymorphism analysis, and PAI-1 plasma activity (chromogenic method) was assessed before and after angioplasty. Following angioplasty, PAI-1 activity increased in 10 of 29 patients and decreased or remained unchanged in 19 of 29. ACE DD genotype was significantly (P=0.04) associated with an increase of PAI-1 activity post angioplasty (OR DD/ID+II=6.5, CI 95% 4.83–8.22). Whereas no effect of PAI-1 4G/5G and AT1R A1166C polymorphisms on PAI-1 response to angioplasty was demonstrated, these data suggest that renin-angiotensin system genes are involved in the regulation of the fibrinolytic response to balloon injury, possibly affecting angiotensin converting enzyme activity. This interaction between the renin-angiotensin system and hemostasis may be a mechanism by which ACE DD genotype affects the risk of restenosis after percutaneous transluminal angioplasty.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Prisco D, Chiarantini E, Boddi M, Rostagno C, Colella A, Gensini GF. Predictive value for thrombotic disease of plasminogen activator inhibitor-1 plasma levels. Int J Clin Lab Res 1993; 23:1.
Huber K, Jorg M, Probst P, Schuster E, Lang I, Kaindl F, Binder BR. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significant reduced risk for coronary restenosis. Thromb Haemost 1992; 67:209.
Strauss BH, Lau HK, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, Fenkell LL, Natarajan MK, Singh I, Teitel JM. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999; 100:1616.
Capanni M, Antonucci E, Chiargui L, Boddi V, Abbate R, Prisco D, Giglioli C, Dabizzi RP, Margheri M, Simonetti I, Gensini GF. Impairment of early fibrinolytic activation after PTCA: a mechanism for restenosis-related clinical recurrence? Fibrinolysis Proteolysis 1999; 13:8.
Vaughan DE, Shen C, Lazos SA. Angiotensin II induces plasminogen activator inhibitor (PAI-1) in vitro. Circulation 1992; 86[Suppl I]:I-557
Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induced plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95:1353.
Van Leeuwen RTJ, Kol A, Andreotti F, Kluft C, Maseri A. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90:362.
Ridker PM, Gaboury CL, Seely EW, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87:1969.
Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995; 96:2515.
Moriyama Y, Ogawa H, Oshima S, Arai H, Misumi K, Yasue H. Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction. Coron Artery Dis 1998; 9:691.
Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin angiotensin system on plasma PAI-1. Hypertension 1998; 32:965.
Margaglione M, Grandone E, Vecchione G, Cappucci G, Giuliani N, Colaizzo D, Celentano C, Panico S, Di Minno G. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol 1997; 17:2082.
Margaglione M, Cappucci G, Giuliani N, Vecchione G, Di Minno G. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18:562.
Dotter CT, Judkins MP. Transluminal treatment of aterosclerotic obstruction: description of a new technique and a preliminary report of its application. Circulation 1964; 30:654.
Gruntzig A. Transluminal dilatation of coronary artery stenosis. Lancet 1978; 1:263.
Chmielewska J, Ranby H, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31:427.
Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992; 20:1433
Katsuja T, Koike G, Yee TW. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995; 345:1600.
The TIMI study group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase one findings. N Engl J Med 1985; 312:932.
Brown BG, Bolson E, Frimer M. Quantitative coronary angiography: estimation of dimensions hemodynamic resistance, and atheroma mass of coronary artery lesions using arteriogram and digital computation. Circulation 1977;55:329.
Simonetti I, De Caterina R, Marzilli M. Coronary vasodilatation by nitrates is not mediated by the prostaglandin system: an angiographic and hemodynamic study. Z Kardiol 1983; 72, 3S:40.
Fatini C, Abbate R, Pepe G, Battaglini B, Gensini F, Ruggiano G, Gensini GF, Guazzelli R. Searching for a better assessment of the individual coronary risk profile: the role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. Eur Heart J 2000; 21:633.
Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F. Deletion polymorphism in the gene for ACE is a potent risk factor for myocardial infarction. Nature 1992; 359:641.
Mattu RK, Needham EWA, Galton DJ, Frangos E, Clark AJL, Caufield M. A DNA variant at the ACE gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation 1995; 91:270.
Tiret L, Bornardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G, Kee F, Ducimetiere P, Soubrier F, Cambien F. Synergistic effects of ACE and AT1R gene polymorphism on risk of myocardial infarction. Lancet 1994; 344:910.
Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95:995.
Johnston CI, Clappison BH, Anderson WP, Yasujima M. Effect of angiotensin converting enzyme inhibition on circulating and local kinin levels. Am J Cardiol 1982; 49:1401.
Emeis JJ. Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann N Y Acad Sci 1992; 667:249.
Brown NJ, Nadeau J, Vaughan DE. Stimulation of tissue-type plasminogen activator in vivo by infusion of bradykinin. Thromb Haemost 1997; 77:522.
Prisco D, Paniccia R, Bandinelli B, Giusti B, Colella A, Comeglio M, Abbate R, Simone I, Gensini GF, Neri Serneri GG. Short-term ACE inhibition may influence exercise-induced changes in haemostasis in healthy subjects. Fibrinolysis Proteolysis 1997; 11:187.
Lottermoser K, Wostmann B, Weisser B, Hertfelder HJ, Schmitz U, Vetter H, Dusing R. Effects of captopril on fibrinolytic function in healthy humans. Eur J Med Res 1999 26; 4:31.
Kim DK, Ryu JC, Rhee CH, Lee WR. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 1997; 17:3242.
Ohishi M, Ueda M, Rakugi H, Okamura A, Naruko T, Becker AE, Hiwada K, Kamitani A, Kamide K, Higaki J, Ogihara T. Upregulation of angiotensin converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. Circulation 1997; 96:3328.
Li J, Wanchun C. Benazepril on tissue angiotensin converting enzyme and cellular proliferation in restenosis after experimental angioplasty. J Cardiovasc Pharmacol 1997; 30:790.
Haberbosch W, Bohle RM, Franke FE, Danilov S, Alhenc Gelas F, Braun R, Holschermann H, Waas W, Tillmanns H, Gardemann A. The expression of the angiotensin I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions. Atherosclerosis 1997; 130:203.
Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, Vado A, Benetton G, Piazza A. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme. A major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998; 97:147
Amant C, Bauters C, Bodart JC, Lablanche JM, Grollier G, Hamon M, Amouyel P, Bertrand M. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997; 96:56.
Hamon M, Bauters C, Amant C, Mc Fadden EP, Lablanche JM, Bertrand ME, Amouyel P. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation 1995; 92:296.
Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 1999; 99:2496.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prisco, D., Fatini, C., Battaglini, B. et al. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. Int J Clin Lab Res 30, 179–185 (2000). https://doi.org/10.1007/s005990070004
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s005990070004